The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer-Reference-Cited by-同舟云学术

The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer

Published:1990-05 Issue:3 Volume:20 Page:365-368
ISSN:0047-1909
Container-title:The Japanese Journal of Surgery
language:en
Short-container-title:The Japanese Journal of Surgery

Author:

Akiyoshi Tsuyoshi,Arinaga Shinya,Nanbara Shigeru,Karimine Nobuya,Inoue Hiroshi,Takamuku Kiyoshi,Abe Ryoji,Watanabe Daisuke,Nagamatsu Masaaki,Matsuoka Hideo,Ueo Hiroaki

Publisher

Springer Science and Business Media LLC

Subject

Surgery,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/BF02470676.pdf

Reference14 articles.

1. Ogura T, Shindo H, Shinzato O, Namba M, Masuno T, Inoue K, Kishimoto S, Yamamura Y.In vitro tumor killing by peritoneal macrophages from mitomycin C treated rats. Cancer Immunol Immunother 1982; 13: 112–117.

2. Shindo H, Ogura T, Masuno T, Hayashi S, Kishimoto S. Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice. Cancer Immunol Immunother 1985; 20: 145–150.

3. Akiyoshi T, Arinaga S, Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C. Cancer Immunol Immunother 1987; 24: 259–262.

4. Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients. Int J Immunopharmacol 1988; 10: 47–51.

5. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–1492.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Laboratory Correlates of Chemoimmunotherapy with Low-Dose Recombinant Interleukin-2 and Mitomycin C in Patients with Advanced Carcinoma;Cancer Investigation;1994-01

2. Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C;Cancer Immunology Immunotherapy;1993-07

3. Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C;Cancer Immunology Immunotherapy;1992-07